Recro Pharma Inc(REPH)- NASDAQ
  • Fri, Sep. 2, 7:52 AM
    • Athenahealth (NASDAQ:ATHN) initiated with Hold rating by Stifel Nicolaus.
    • Juno Therapeutics (NASDAQ:JUNO) initiated with Sell rating and $23 (15% downside risk) price target by BTIG Research. Initiated coverage on Kite Pharma (NASDAQ:KITE) with Neutral rating.
    • Gemphire Therapeutics (Pending:GEMP) initiated with Buy rating and $17 (26% upside) price target by Canaccord Genuity. Initiated with Outperform rating and $25 (86% upside) price target by RBC Capital.
    • Galapagos NV (NASDAQ:GLPG) initiated with Buy rating and $64 (18% upside) price target by Janney Capital.
    • Sophiris Bio (NASDAQ:SPHS) initiated with Overweight rating and $7 (138% upside) price target by Piper Jaffray.
    • Cantel Medical (NYSE:CMN) initiated with Buy rating and $83 (9% upside) price target by Benchmark.
    • Recro Pharma (NASDAQ:REPH) initiated with Buy rating and $21 (122% upside) price target by Janney Montgomery Scott.
    • Theravance Biopharma (NASDAQ:TBPH) initiated with Buy rating and $41 (42% upside) price target by Evercore ISI.
    • Intuitive Surgical (NASDAQ:ISRG) initiated with Outperform rating by Raymond James.
    | Fri, Sep. 2, 7:52 AM
  • Wed, Aug. 24, 9:04 AM
    • Insys Therapeutics (NASDAQ:INSY) is ahead 9% premarket on increased volume in response to its announcement of successful results in its Phase 3 study assessing Buprenorphine Sublingual Spray for the treatment of moderate-to-severe postoperative pain in patients undergoing bunionectomy, a procedure that requires an incision on the top or side of the big toe joint.
    • The primary endpoint was the summed pain intensity difference over 48 hours. The three dosages of Buprenorphine evaluated (0.5 mg 3x/day, 0.25 mg 3x/day, 0.125 mg 3x/day) were all statistically significantly better than placebo with the highest dose showing the largest reduction (expected for a pain medication).
    • The company plans to discuss the results with the FDA by year end as well as the steps required to file a New Drug Application (NDA).
    • Update: Slingshot Insights has a proposed expert interview to better understand these results as well as Recro Pharma's (NASDAQ:REPH) late-stage data on IV meloxicam. Astute investors will want to participate.
    | Wed, Aug. 24, 9:04 AM | 9 Comments
  • Wed, Aug. 17, 7:05 AM
    • Recro Pharma (NASDAQ:REPH) prices its public offering of 1,986,666 shares of common stock at $7.50. Closing date is August 19. Net proceeds will fund the continued clinical development of injectable meloxicam and general corporate purposes.
    • Yesterday's close was $8.60 so expect a down day.
    | Wed, Aug. 17, 7:05 AM
  • Thu, Aug. 11, 7:15 AM
    • Recro Pharma (NASDAQ:REPH): Q2 EPS of -$0.83 misses by $0.05.
    • Revenue of $17.28M (-7.4% Y/Y) beats by $1.85M.
    • Press Release
    | Thu, Aug. 11, 7:15 AM
  • Wed, Jul. 27, 12:44 PM
    | Wed, Jul. 27, 12:44 PM
  • Wed, Jul. 27, 11:00 AM
    | Wed, Jul. 27, 11:00 AM | 3 Comments
  • Wed, Jul. 27, 10:09 AM
    • Ultra-thinly traded nano cap Recro Pharma (REPH +37%) heads north on a 7x surge in volume, albeit on turnover of only 105K shares, in response to its announcement of positive results from a 201-subject Phase 3 clinical trial assessing intravenous (IV) meloxicam for the treatment of acute postoperative pain in patients following bunionectomy surgery, a painful procedure that requires an incision in the top or side of the big toe joint.
    • The study met its primary endpoint of showing a statistically valid reduction in pain intensity over 48 hours compared to placebo (p=0.0034). Participants were randomized 1:1 to receive either a postoperative regimen of IV meloxicam (30 mg bolus injection over 15-30 seconds) or placebo once every 24 hours up to three times.
    • IV meloxicam was well tolerated with non serious adverse events or bleeding events reported.
    • The company intends to submit additional data from the study for presentation at a future scientific conference or for publication.
    • A second Phase 3 evaluating IV meloxicam in abdominoplasty surgery is ongoing. Top-line results should be available in Q4. If all goes well, a New Drug Application (NDA) will be submitted to the FDA in mid-2017.
    • Meloxicam is an anti-inflammatory and analgesic agent called a COX-2 inhibitor. It has been marketed since the 1990s in an oral formulation by Boehringer Ingelheim. Recro acquired the rights to the intravenous/intramuscular formulation from Alkermes in April 2015.
    | Wed, Jul. 27, 10:09 AM
  • Tue, Jul. 5, 4:46 PM
    • Recro Pharma (NASDAQ:REPH) appoints Michael Celano as Chief Financial Officer effective immediately. Previously, he was Principal and Founder of Lafayette Hill Consulting.
    | Tue, Jul. 5, 4:46 PM
  • Thu, May 12, 9:12 AM
    • Recro Pharma (NASDAQ:REPH): Q1 EPS of -$0.71 misses by $0.05.
    • Revenue of $17.74M beats by $4.74M.
    • Press Release
    | Thu, May 12, 9:12 AM
  • Tue, Apr. 5, 12:45 PM
    | Tue, Apr. 5, 12:45 PM | 10 Comments
  • Thu, Mar. 24, 8:46 AM
    • Recro Pharma (REPH) FY15 results: Revenues: $52M; R&D Expense: $12.3M (+55.7%); SG&A: $13M (+225.0%); Operating Loss: ($7M) (+41.2%); Net Income: $3M (+117.2%); EPS: $0.21 (+107.5%); Quick Assets: $19.8M (+0.5%).
    • No guidance given.
    | Thu, Mar. 24, 8:46 AM
  • Thu, Mar. 24, 8:29 AM
    • Recro Pharma (NASDAQ:REPH): FY15 EPS of $0.21
    • Revenue of $52M
    | Thu, Mar. 24, 8:29 AM | 1 Comment
  • Tue, Feb. 16, 12:40 PM
    • Recro Pharma (REPH +1%) appoints Fred Graff as Chief Commercial Officer. Previously, he was a strategic consultant. His background includes stints at Sepracor Pharmaceuticals, Vanda Pharmaceuticals and Rhone Poulenc Rorer.
    | Tue, Feb. 16, 12:40 PM
  • Mon, Feb. 1, 11:13 AM
    • Dosing is underway in Recro Pharma's (REPH -0.9%) second Phase 3 clinical trial assessing IV meloxicam for the treatment of acute pain following bunionectomy surgery.
    • The double-blind, placebo-controlled study will randomize ~200 patients to receive either 30 mg of IV meloxicam or placebo once every 24 hours for up to three days following surgery. The primary efficacy endpoint is the summed pain intensity difference over the first 48 hours versus placebo. Top-line data are expected by year-end.
    • A Phase 2 study showed statistically significant reductions in pain intensity in patients receiving IV meloxicam.
    • Meloxicam is an anti-inflammatory and analgesic agent called a COX-2 inhibitor. It has been marketed since the 1990s in an oral formulation by Boehringer Engelheim. Recro acquired the rights to the intravenous/intramuscular formulation from Alkermes in April 2015. Bunionectomy surgery is a very painful procedure that requires an incision in the top or side of the big toe joint.
    • Previously: Recro Pharma's IV meloxicam successful in mid-stage study (Jan. 6)
    | Mon, Feb. 1, 11:13 AM
  • Wed, Jan. 6, 10:52 AM
    • Results from a Phase 2 clinical trial assessing one of Recro Pharma's (REPH +0.5%) lead product candidates, intravenous (IV) meloxicam, for the treatment of acute pain following bunionectomy surgery showed it to be both safe and effective.
    • The primary efficacy endpoint was the difference in pain intensity over 48 hours after surgery versus placebo as measured by a rating scale called Summed Pain Intensity Difference (SPID48). Both the 30 mg dose of IV meloxicam and the 60 mg dose showed statistically significant reductions in post-surgery pain compared to placebo (p=0.007 and p=0.0027, respectively).
    • IV meloxicam was well tolerated with no serious adverse events, bleeding events or injection site reactions observed. The most common adverse events were nausea, headache, dizziness, itchy skin and vomiting. There were no treatment discontinuations due to adverse events.
    • Meloxicam is an anti-inflammatory and analgesic agent called a COX-2 inhibitor. It has been marketed since the 1990s in an oral formulation by Boehringer Ingelheim. Recro acquired the rights to the intravenous/intramuscular formulation from Alkermes in April 2015. A Phase 3 study should commence this quarter.
    • Bunionectomy surgery is a very painful procedure that requires an incision in the top or side of the big toe joint.
    • Previously: Recro Pharma completes acquisition of certain Alkermes assets; Shares rise (April 13, 2015)
    | Wed, Jan. 6, 10:52 AM
  • Nov. 13, 2015, 10:31 AM
    • Recro Pharma (REPH -4.2%) Q3 results: Revenues: $16.5M; R&D Expense: $2.7M (-25.0%); SG&A: $3.5M (+218.2%); Operating Loss: ($0.2M) (+95.7%); Net Loss: ($2.2M) (+53.2%); Loss Per Share: ($0.24) (+60.7%); Quick Assets: $28.3M (+43.7%).
    • No guidance given.
    | Nov. 13, 2015, 10:31 AM | 1 Comment